Assessment of association between immune related adverse events and efficacy in patients treated with inoperable or metastatic Melanoma
Latest Information Update: 19 Jul 2022
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
Most Recent Events
- 19 Jul 2022 New trial record
- 01 Jun 2022 Results published in the Journal of Dermatological Treatment